KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oscar Health (OSCR) Other Non-Current Liabilities (2021 - 2025)

Oscar Health (OSCR) has disclosed Other Non-Current Liabilities for 6 consecutive years, with $52.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Liabilities fell 15.16% year-over-year to $52.0 million, compared with a TTM value of $52.0 million through Dec 2025, down 15.16%, and an annual FY2025 reading of $52.0 million, down 15.16% over the prior year.
  • Other Non-Current Liabilities was $52.0 million for Q4 2025 at Oscar Health, down from $55.8 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $77.1 million in Q1 2022 and bottomed at $52.0 million in Q4 2025.
  • Average Other Non-Current Liabilities over 5 years is $66.6 million, with a median of $67.6 million recorded in 2023.
  • The sharpest move saw Other Non-Current Liabilities soared 412.09% in 2021, then decreased 15.16% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $76.8 million in 2021, then decreased by 5.93% to $72.3 million in 2022, then fell by 6.51% to $67.6 million in 2023, then dropped by 9.31% to $61.3 million in 2024, then fell by 15.16% to $52.0 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for OSCR at $52.0 million in Q4 2025, $55.8 million in Q3 2025, and $57.3 million in Q2 2025.